Eli Lilly Invests $5.3 Billion in Boone County Operations

Lilly CEO on expansion: 'The currency is speed' – Inside INdiana Business

Eli Lilly and Co. invested an additional $5.3 billion in its Boone County operations, totaling $9 billion, to enhance manufacturing capabilities. The investment decision was influenced by the proximity to research and development facilities and the state's support for large-scale projects.

Eli Lilly and Company

Eli Lilly Hits New 12-Month High

Eli Lilly and Company (NYSE:LLY) Hits New 12-Month High at $826.21

Eli Lilly and Company reached a new 52-week high of $826.21 and last traded at $822.65. Several investment firms, including Barclays, Morgan Stanley, Argus, Cantor Fitzgerald, and BMO Capital Markets, upgraded Eli Lilly's target price and rating.

Eli Lilly Presents Updated Data on Olomorasib at ASCO Annual Meeting

Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the ...

Eli Lilly and Company presented updated data from the Phase 1/2 study of olomorasib for KRAS G12C-mutant advanced solid tumors at the 2024 ASCO Annual Meeting. The study detailed olomorasib monotherapy efficacy in various solid tumors and its combination with pembrolizumab in KRAS G12C-mutant advanced NSCLC.

Lilly, Amazon Pump Billions into Indiana's Industrial Resurgence

Lilly, Amazon pump billions into Indiana’s industrial resurgence

Eli Lilly & Co. pledged to invest $5.3 billion in Indiana to expand a site for drug manufacturing. Amazon Web Services announced an $11 billion investment in the state, marking the largest capital commitment in Indiana's history.

Eli Lilly Invests $5.3 Billion in Indiana Manufacturing Site

LLY: 3 Pharma Stocks Poised for Big Returns This Summer

Eli Lilly announced a $5.3 billion investment in its Lebanon, Indiana, manufacturing site to enhance its capacity for producing Active Pharmaceutical Ingredients (API).

Eli Lilly's Zepbound to Make Weight-Loss Market Worth $130B

Eli Lilly's Zepbound to make weight-loss market worth $130B: Goldman

Goldman Sachs forecasts that the weight-loss drug market will be worth $130 billion by 2030, a $30 billion increase from its previous projection. Eli Lilly's stock value rose to $775 billion, surpassing Tesla's $550 billion market cap.

Revolutionary Weight Loss Drugs: Navigating Investment Opportunities in Eli Lilly and Novo Nordisk

Revolutionary weight loss drugs: navigating investment opportunities in Eli Lilly and Novo Nordisk

Eli Lilly's Tirzepatide achieved a remarkable weight loss result of over 15% in Phase 3 clinical trials, positioning the company at the forefront of the weight loss drug market. Healthy Living ETF has significantly invested in Eli Lilly and Novo Nordisk.

Lilly Endowment Inc Sells Eli Lilly Shares Worth Over $1.66 Million

Lilly Endowment Inc sells Eli Lilly shares worth over $1.66 million By Investing.com

Lilly Endowment Inc sold 2,052 shares of Eli Lilly & Co on May 28, 2024, at a price of $809.0 per share, resulting in a total sale value of $1,660,068.

Eli Lilly's Weight Loss Drugs Drive Strong Growth in 2024

Institutional Bets: 7 Stocks the Big Money Will Send Higher This Year

Eli Lilly's weight loss drugs, Zepbound and Mounjaro, have contributed significantly to revenue increases in 2024, driving strong growth for the company.

Lilly Endowment Inc sells over $105 million in Eli Lilly stock

Lilly Endowment Inc sells over $105 million in Eli Lilly stock By Investing.com

Lilly Endowment Inc sold over $105 million worth of Eli Lilly & Co stock on May 29, 2024, in multiple transactions at prices ranging from $809.345 to $815.35, resulting in a significant reduction of its holdings in Eli Lilly.

Eli Lilly and Company is an American pharmaceutical company committed to creating high-quality medicines that make life better for people around the world. Founded in 1876, the company has a long history of pharmaceutical innovation and has a global presence with products sold in approximately 125 countries.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

COM:LILLY

Eli Lilly and Company

Last Close

753.41

21/11 20:51

Market Cap

893.17B

Beta: -

Volume Today

3.05M

Avg: -

Analysis Not Available